OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)

被引：0
作者：
Corman, J. [1 ]
Dawson, N. [2 ]
Hall, S. [3 ]
Nabhan, C. [4 ]
Ferrari, A. [5 ]
Armstrong, A. J. [6 ]
Murdock, M. I. [7 ]
Stewart, F. [8 ]
Sheikh, N. [9 ]
Petrylak, D. P. [10 ]
机构：
[1] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[2] Georgetown Univ, Washington, WA USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
[5] NYU, Ctr Canc, New York, NY USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
[7] Murdock Urol Associates, Urol, Greenbelt, MD USA
[8] Dendreon Corp, Biometr, Seattle, WA USA
[9] Dendreon Corp, Clin Immunol, Seattle, WA USA
[10] Columbia Univ, Med Ctr, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
[31]   A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. [J].
Karzai, Fatima ;
Madan, Ravi Amrit ;
Owens, Helen ;
Couvillon, Anna ;
Hankin, Amy ;
Williams, Monique ;
Bilusic, Marijo ;
Cordes, Lisa M. ;
Trepel, Jane B. ;
Killian, Keith ;
Meltzer, Paul S. ;
Gulley, James L. ;
Lee, Jung-min ;
Dahut, William L. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[32]   IMPACT OF SALVAGE THERAPY WITH APC8015F ON THE OVERALL SURVIVAL (OS) BENEFIT ACHIEVED WITH SIPULEUCEL-T IN THREE PHASE 3 STUDIES OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) [J].
George, D. J. ;
Gomella, L. G. ;
Devries, T. ;
Whitmore, J. B. ;
Frohlich, M. W. ;
Nabhan, C. .
ANNALS OF ONCOLOGY, 2012, 23 :310-310
[33]   Impact of salvage therapy with APC8015F on the overall survival (OS) benefit achieved with sipuleucel-T in three phase III studies of metastatic castrate-resistant prostate cancer (mCRPC) [J].
Gomella, Leonard G. ;
Nabhan, Chadi ;
DeVries, Todd ;
Whitmore, James Boyd ;
Frohlich, Mark Walter ;
George, Daniel J. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[34]   Evaluation of patients, safety, and financial implications of sipuleucel-T (SipT) for treatment of metastatic castrate-resistant prostate cancer (mCRPC): Early real-world experience at USC. [J].
Pak, S. ;
Reed, M. ;
Luther, M. ;
Averia, M. ;
Desai, S. ;
Pinski, J. K. ;
Dorff, T. B. ;
Quinn, D. I. ;
Chan, B. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[35]   Sipuleucel-T In Metastatic Castration-Resistant Prostate Cancer [J].
Plosker, Greg L. .
DRUGS, 2011, 71 (01) :101-108
[36]   Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study [J].
Gardner, Thomas A. ;
Petrylak, Daniel Peter ;
Corman, John M. ;
Hall, Simon ;
Weinstein, Ralph ;
Keyser, Robert ;
Sims, Robert Brownell ;
Sanders, Amanda ;
Sheikh, Nadeem A. ;
Higano, Celestia S. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[37]   Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer (CRPC). [J].
Park, Jong Chul ;
Sartor, A. Oliver ;
Sullivan, Rana ;
King, Serina ;
Antonarakis, Emmanuel S. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[38]   Time to disease-related pain (TDRP) following sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Integrated results from three randomized phase 3 trials [J].
Small, E. J. ;
Higano, C. S. ;
Kantoff, P. W. ;
Whitmore, J. B. ;
Frohlich, M. W. ;
Petrylak, D. P. .
EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) :E123-U509
[39]   Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC). [J].
Kohli, Manish ;
Huang, Xiaoyi ;
Yuan, Tiezheng ;
Sun, Zhifu ;
Costello, Brian Addis ;
Quevedo, Fernando ;
Tan, Winston ;
Nandy, Debashis ;
Longenbach, Sherri ;
Wang, Liang .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[40]   Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC) [J].
Zist, A. ;
Amir, E. ;
Ocana, A. ;
Seruga, B. .
EUROPEAN JOURNAL OF CANCER, 2013, 49 :S703-S703
12345